What does Diasorin sell?
DiaSorin sells a comprehensive portfolio of medical diagnostic test kits, immunoassay reagents, molecular diagnostic assays, and fully automated laboratory instruments to hospitals, commercial reference laboratories, and research institutions worldwide. Their product offerings cover a vast spectrum of clinical testing categories, including infectious disease detection, bone metabolism evaluation, endocrine function assessments, oncology markers, and quantitative tests for various viral pathogens. Alongside physical diagnostic kits and chemical reagents, the company sells and leases sophisticated laboratory analyzers, such as the LIAISON instrument family, which allow clinical facilities to process high volumes of patient blood and fluid samples quickly, safely, and accurately.
Related FAQs
The DiaSorin LIAISON XL automated analyzer features a maximum analytical throughput of up to 180 tests per hour (with specific configurations running between 171 and 180 tests per hour depending on assay protocols), designed for high-volume random-ac...
DiaSorin S.p.A. generates annual revenues of approximately $1.40 billion USD, reflecting its strong global presence as a multinational biotechnology leader specializing in immunodiagnostic and molecular diagnostic testing solutions.
Yes, DiaSorin S.p.A. is a public company. Its shares are listed and traded on the Borsa Italiana (the Italian Stock Exchange) under the ticker symbol "DIA.
DiaSorin S.p.A. is a prominent global leader in the laboratory diagnostics market, specializing in immunodiagnostics and molecular diagnostics.
Yes, Diasorin is a global leader in the biotechnology and diagnostic sector. The company specializes in the development, production, and commercialization of diagnostic tests for a wide range of clinical conditions.
"DIC" can refer to multiple entities depending on the sector.
DiaSorin S.p.A. is a multinational Italian biotechnology company that operates as a global leader in the field of immunodiagnostics and molecular diagnostics.
DiaSorin reports multi-billion-euro equivalent revenues (surpassing €1.3 billion to €1.4 billion in annual tracking), underpinned by continuous global demand for specialized clinical laboratory diagnostics.
Yes, DiaSorin is an Italian multinational company. It is headquartered in Saluggia, in the Piedmont region of Italy.
The proper noun and corporate name DiaSorin does not translate to a literal word in standard dictionaries, as it is a specialized corporate identity formed from a combination of terms associated with its medical diagnostic origins.
Yes, DiaSorin officially acquired Luminex Corporation in 2021 for approximately $1.8 billion.
The DiaSorin LIAISON® XL is a sophisticated, fully automated immunoassay analyzer engineered for high-throughput clinical and research laboratories.
Citrix Systems, operating as a core component under private equity ownership and cloud software consolidation strategies, historically generated annual revenues approaching $3 billion to $3.2 billion USD.
Market analysts are currently divided on Diasorin (DSR), with a consensus that leans toward "Hold" rather than a definitive buy or sell.
The official operational and laboratory facility address for Diasorin Molecular LLC in Austin, Texas, is located at 12112 Technology Blvd, Suite 130, Austin, TX 78727.
DiaSorin is primarily classified as an in vitro diagnostics (IVD) company, which places it within the broader medical equipment and biotechnology sectors.
Telenor ASA generates annual revenues approaching NOK 77 billion (translating to approximately $7.2 billion to $7.